Show simple item record

dc.contributor.authorKernagis, Dawn N
dc.contributor.authorBalcer-Kubiczek, Elizabeth
dc.contributor.authorBazyar, Soha
dc.contributor.authorOrschell, Christie M
dc.contributor.authorJackson, Isabel L
dc.date.accessioned2022-11-22T16:09:27Z
dc.date.available2022-11-22T16:09:27Z
dc.date.issued2022-06-09
dc.identifier.urihttp://hdl.handle.net/10713/20207
dc.description.abstractMore than 50 years after the Apollo missions ended, the National Aeronautical and Space Administration (NASA) and other international space agencies are preparing a return to the moon as a step towards deep space exploration. At doses ranging from a fraction of a Gray (Gy) to a few Gy, crew will be at risk for developing bone marrow failure associated with the hematopoietic subsyndrome of acute radiation syndrome (H-ARS) requiring pharmacological intervention to reduce risk to life and mission completion. Four medical countermeasures (MCM) in the colony stimulating factor class of drugs are now approved for treatment of myelosuppression associated with ARS. When taken in conjunction with antibiotics, fluids, antidiarrheals, antiemetics, antipyretics, and other treatments for symptomatic illness, the likelihood for recovery and mission completion can be greatly improved. The current review describes the performance and health risks of deep space flight, ionizing radiation exposure during crewed missions to the moon and Mars, and U.S. Food and Drug Administration (FDA)-approved medical interventions to treat ARS. With an expansion of human exploration missions beyond low Earth orbit (LEO), including near-term Lunar and future Mars missions, inclusion of MCMs to counteract ARS in the spaceflight kit will be critical for preserving crew health and performance.en_US
dc.description.urihttps://doi.org/10.1016/j.lssr.2022.06.002en_US
dc.language.isoenen_US
dc.relation.ispartofLife sciences in space researchen_US
dc.rightsCopyright © 2022. Published by Elsevier B.V.en_US
dc.subjectDeep Space Explorationen_US
dc.subjectMedical Countermeasuresen_US
dc.subjectSpace Flightkiten_US
dc.subjectSpace Radiationen_US
dc.titleMedical countermeasures for the hematopoietic-subsyndrome of acute radiation syndrome in space.en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.lssr.2022.06.002
dc.identifier.pmid36336367
dc.source.journaltitleLife sciences in space research
dc.source.volume35
dc.source.beginpage36
dc.source.endpage43
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record